去势抵抗性前列腺癌的药物治疗现状

doi:10.11904/j.issn.1002-3070.2021.04.015

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (4): 376-379.doi: 10.11904/j.issn.1002-3070.2021.04.015

去势抵抗性前列腺癌的药物治疗现状

高科综述, 任明华校审

哈尔滨医科大学附属第一医院泌尿外科(哈尔滨 150000)

收稿日期:2020-09-10 修回日期:2020-10-28 出版日期:2021-08-28 发布日期:2021-08-24
通讯作者: 任明华,E-mail:renminghua1972@163.com
作者简介:高科,男,(1994-),硕士研究生,从事泌尿系统肿瘤的研究。
基金资助:
黑龙江省自然科学基金(编号:LH2019H030)

Current status of drug therapy for castration-resistant prostate cancer

GAO Ke, REN Minghua

Department of Urinary Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin 150000,China

Received:2020-09-10 Revised:2020-10-28 Online:2021-08-28 Published:2021-08-24

摘要/Abstract

摘要： 雄激素剥夺疗法(ADT)一直是晚期前列腺癌的代表性疗法。当前列腺癌进展为去势抵抗性前列腺癌(CRPC)时,ADT的抗性也随之出现。目前,多西他赛是首个被美国食品药品监督管理局(FDA)批准用于CRPC的细胞毒性化疗药物。另外,还有阿比特龙、恩杂鲁胺等药物也获得FDA批准,且这些药物都显示出良好的生存获益。本文对这些疗法的临床试验和生存获益进行了回顾,并对这一领域的新兴药物进行了讨论。本综述将对CRPC的药物治疗现状进行陈述,并为临床用药提供参考。

关键词: 前列腺癌, 去势抵抗性前列腺癌, 药物治疗

Abstract: Androgen deprivation therapy(ADT)has always been a representative therapy for advanced prostate cancer.When prostate cancer progresses to castration resistant prostate cancer(CRPC),ADT resistance also emerges.Currently,docetaxel is the first cytotoxic chemotherapy drug approved for CRPC.In addition,abiraterone,enzalutamide and other drugs have also been approved by FDA,and these drugs have shown good survival benefits.In this article,we reviewed the clinical trials and survival benefits of these therapies,and discussed emerging drugs in this field.This review will describe the current status of CRPC drug treatment and provide references for clinical medication.

Key words: Prostate cancer, Castration-resistant prostate cancer(CRPC), Drug therapy

中图分类号:

R737.25

高科, 任明华. 去势抵抗性前列腺癌的药物治疗现状[J]. 实用肿瘤学杂志, 2021, 35(4): 376-379.

GAO Ke, REN Minghua. Current status of drug therapy for castration-resistant prostate cancer[J]. Journal of Practical Oncology, 2021, 35(4): 376-379.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.04.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I4/376

参考文献

1 Miller KD,Nogueira L,Mariotto AB,et al.Cancer treatment and survivorship statistics[J].CA Cancer J Clin,2019,69(5):363-385.
2 Teoh JYC,Hirai HW,Ho JMW,et al.Global incidence of prostate cancer in developing and developed countries with changing age structures[J].PLoS One,2019,14(10):e0221775.
3 Rasool RU,Natesan R,Deng Q,et al.CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation[J].Cancer Discov,2019,9(11):1538-1555.
4 Yu J,Sun L,Hao T,et al.Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer[J].Ann Transl Med,2019,7(23):729.
5 Dong L,Zieren RC,Xue W,et al.Metastatic prostate cancer remains incurable,why?[J].Asian J Urol,2019,6(1):26-41.
6 中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.
7 Mohler JL,Antonarakis ES,Armstrong AJ,et al.Prostate cancer,version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(5):479-505.
8 James A,Vincent B,Sivadas A,et al.A study on the clinical outcome of abiraterone acetate in castration resistant prostate cancer patients[J].Int J Hematol Oncol Stem Cell Res,2018,12(1):4-7.
9 Yuan F,Hankey W,Wu D,et al.Molecular determinants for enzalutamide-induced transcription in prostate cancer[J].Nucleic Acids Res,2019,47(19):10104-10114.
10 Hussain M,Fizazi K,Saad F,et al.Enzalutamide in men with non-metastatic,castration-resistant prostate cancer[J].N Engl J Med,2018,378(26):2465-2474.
11 David L,Joaquin M,Raquel PL,et al.Sequencing of agents in castration-resistant prostate cancer[J].Lancet Oncology,2015,16(6):279-292.
12 Markham A,Duggan S.Darolutamide:first approval[J].Drugs,2019,79(16):1813-1818.
13 Zurth C,Sandmann S,Trummel D,et al.Blood-brain barrier penetration of [14C] darolutamide compared with [14C] enzalutamide in rats using whole body autoradiography[J].J Clin Oncol,2018,36(Suppl 6S):345.
14 Saad F,Aprikian A,Finelli A,et al.2019 Canadian Urological Association(CUA)-Canadian Uro Oncology Group(CUOG)guideline:management of castration-resistant prostate cancer(CRPC)[J].Can Urol Assoc J,2019,13(10):307-314.
15 He D,Sun Z,Guo J,et al.A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China[J].Asia Pac J Clin Oncol,2019,15(3):144-150.
16 Al-Mansouri L,Gurney H.Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer[J].Asia Pac J Clin Oncol,2019,15(6):288-295.
17 Komura K,Sweeney CJ,Inamoto T,et al.Current treatment strategies for advanced prostate cancer[J].Int J Urol,2018,25(3):220-231.
18 Higano CS,Armstrong AJ,Sartor AO,et al.Real-world outcomes of sipuleucel-T treatment in PROCEED,a prospective registry of men with metastatic castration-resistant prostate cancer[J].Cancer,2019,125(23):4172-4180.
19 Antonarakis ES,Piulats JM,Gross-Goupil M,et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort,open-label phase II KEYNOTE-199 study[J].J Clin Oncol,2020,38(5):395-405.
20 Kumar A,Dhar S,Campanelli G,et al.MTA1 drives malignant progression and bone metastasis in prostate cancer[J].Mol Oncol,2018,12(9):1596-1607.
21 Gallicchio R,Mastrangelo PA,Nardelli A,et al.Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer:when and why[J].Tumori,2019,105(5):367-377.
22 Rizzini EL,Dionisi V,Ghedini P,et al.Clinical aspects of mCRPC management in patients treated with radium-223[J].Sci Rep,2020,10(1):6681.
23 Baba K,Kaida H,Hattori C,et al.Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases[J].Hell J Nucl Med,2018,21(1):15-23.
24 Zakaly HMH,Mostafa MYA,Deryabina D,et al.Comparative studies on the potential use of 177Lu-based radiopharmaceuticals for the palliative therapy of bone metastases[J].Int J Radiat Biol,2020,96(6):779-789.
25 武俊平,陈婷婷,宋文华,等.康艾注射液联合多西他赛及泼尼松治疗骨转移激素抵抗性前列腺癌的疗效观察[J].空军医学杂志,2018,34(2):115-118.
26 陈浩然,刘浩.中医药防治去势抵抗性前列腺癌的思路与方法[J].中华中医药学刊,2021,39(3):164-168.
27 Tuguzbaeva G,Yue E,Chen X,et al.PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting αv integrin/FAK/Src signaling in oral squamous cell carcinoma cells[J].Acta Pharm Sin B,2019,9(6):1163-1173.
28 Yu S,Li L,Tian W,et al.PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition[J].Br J Pharmacol,2018,175(15):3111-3130.
29 Martellucci S,Clementi L,Sabetta S,et al.Src family kinases as therapeutic targets in advanced solid tumors:what we have learned so far[J].Cancers(Basel),2020,12(6):1448.
30 Hwang S,Takimoto T,Hemler ME.Integrin-independent support of cancer drug resistance by tetraspanin CD151[J].Cell Mol Life Sci,2019,76(8):1595-1604.
31 De Felice F,Tombolini V,Marampon F,et al.Defective DNA repair mechanisms in prostate cancer:impact of olaparib[J].Drug Des Devel Ther,2017,11:547-552.
32 Robinson D,Van Allen EM,Wu YM,et al.Integrative clinical genomics of advanced prostate cancer[J].Cell,2015,161(5):1215-1228.
33 Hussain M,Mateo J,Fizazi K,et al.PROfound:Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer(mCRPC)with homologous recombination repair(HRR)gene alterations[J].Ann Oncol,2019,30:881-882.
34 包乐,唐丽萍.EphB6受体在恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2020,34(1):83-87.

[1]	苗鹏程, 康印东, 李富东, 孟冬冬, 王东星, 常德辉. lncRNA SNHGs在前列腺癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 446-450.
[2]	赵颖欣, 秦玲. 二甲双胍与多发性骨髓瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 476-479.
[3]	姜涛, 张旭. 孤儿核受体在前列腺癌中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 377-380.
[4]	毛高才，朱其聪，沈宏峰，涂瑞沙，闫庆国. 膀胱与前列腺交界处多向分化癌3例临床病理分析[J]. 实用肿瘤学杂志, 2016, 30(6): 538-542.
[5]	牛德方，崔岩，综述，陈辉，审校. CyclinD1表达与泌尿系统肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 547-550.
[6]	沈倩, 尹玉平, 于世英. 165例癌痛患者癌症相关神经病理性疼痛的诊疗现状调查[J]. 实用肿瘤学杂志, 2012, 26(4): 343-347.
[7]	赵锐, 孔祥波, 金宁, 张刚. siRNA干扰cytohesins导致前列腺癌细胞中IGFR信号减低[J]. 实用肿瘤学杂志, 2011, 25(4): 361-364.
[8]	李洁冰, 张艳华, 程文, 张本平. 三维能量多普勒对前列腺癌分化程度研究[J]. 实用肿瘤学杂志, 2010, 24(5): 413-414.
[9]	吴迪综述, 张艳华审校. 经直肠三维超声在前列腺癌诊断中的应用进展[J]. 实用肿瘤学杂志, 2009, 23(5): 496-500.
[10]	乔振奎, 徐万海, 王晓民, 苏宇. 白藜芦醇对人前列腺癌PC-3细胞株VEGF的表达及细胞增殖的影响^△[J]. 实用肿瘤学杂志, 2009, 23(3): 242-24.
[11]	朱芳. Survivin蛋白在前列腺癌组织中表达及临床意义的meta分析[J]. 实用肿瘤学杂志, 2007, 21(05): 453-456.
[12]	何晓燕;骆利康;郑俊. AMACR在前列腺癌诊断与鉴别诊断中的应用[J]. 实用肿瘤学杂志, 2007, 21(04): 342-343.
[13]	赵维明;徐勇;王燕铭;程兆康;张素爱;于琦;孔德领. 壳聚糖纳米粒介导的CD基因对前列腺癌的体外杀伤作用[J]. 实用肿瘤学杂志, 2006, 20(06): 513-516,.
[14]	黄赖机;张秀萍;李健;邓瑾;P.LABAT;I.NATALIE. 三维适形放疗技术在局限性前列腺癌治疗中的应用[J]. 实用肿瘤学杂志, 2005, 19(05): 374-376.
[15]	王俊峰;郑敏;刘春波;郑淼. 经直肠能量多普勒超声在前列腺癌诊断中的价值[J]. 实用肿瘤学杂志, 2005, 19(01): 33-34.

去势抵抗性前列腺癌的药物治疗现状

Current status of drug therapy for castration-resistant prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价